

**Table S3. SBCGs (391) compiled for metastasis of primary breast and prostate cancer to bone.**

<b>SBCGs compiled for metastasis of primary breast cancer to bone</b>	
<b>Gene Symbol</b>	<b>Reference</b>
LRRC15, MMP13, MMP2, BCAM, COL10A1, AEBP1, IGFBP4, ESR1, AEBP1, ASPN, ATP6V0C, BCAM, COMP, CRIP1, DPT, IGFBP4, LRRC15, LRP1, MAB21L2, MMP13, MMP2, PDLIM7, PTOV1, PCDHGC3, RFNG, STK32B, TBC1D10B, TCIRG1, ZNF444	[1]
COX2, PGE2, TNFSF11, TNFRSF11A, FGF7, PTX3, NID2, RAP1GDS1, NPNT, COL6A3, IFIT3, IGRC, FMOD, IGIT1B, EGR1, PTGS2, CXCL10, VCAM1, FGF7, PTN, CD1D, LAMB1, CCL5, SFRP2, CXCL1	[2]
RASSF1A, MGMT, RAR- $\beta$ 2, APC	[3]
IBSP, SPP1, FGF13, COX7B2, SPARC, PRG1, GJA1, SOCS2, EDN1, IL11, CYR61, IGFBP4, IL8, PLAU, FST, MADH3, PTGS2, EXTL2, CTGF, CFBF, CDH11, S100A4, TIMP3, NOG, TGFA, THBS1, IGFBP3, PLAT, TIMP2, FN1, CCNB1, LRPAP1, MMP1, COL5A1, COL8A1, CALB2, CYR61, CTGF, WISP, BMP2, IL11, FST, CXCR4, ADAMTS1, MMP1, CX43, DUSP1, NOG, COX2, CFBF, GJA1, THBS1	[4]
SERPINB5	[5]
ABCB1, ESR1, RUNDC3B, RAP2A	[6]
CSFIR	[7]
CAV1	[8]
TGFB1, ATF3, MMP13, CCNA1	[9]
COL1A1, VIM, S100A4, ACTA2, PDGFRB, NG2, CXCL1, CXCL5, PTGS2	[10]
HISTIH2AC, POMZP3, PON2, TMC5, SCNN1A, C10orf116, NAP1L3, GPRD5C, CTGF, FHL1, DUSP1, DLC1, SOCS2, IL11, ADAMTS1, CYP1B1, SAA2, SAA1, PPL, IL11, SPANXB1, FST, SERPINA1, HLA-DRA, HLA-DPA1, ABCC3, CSGALNACT1, FKBP11, CXCR4, PRG1, SES7-1, SOX4, KHDRBS3, FGF5, C14orf1139, PTX7, MCAM, TGFB1, S100A2, MMP1, FGF5, RGC32	[11]
TFF1, TFF3, AGR2, NAT1, CRIP1, TNRC9, SCUBE2, TNRC9, CYP2B6, RND1, DLALT1, KIF5C, PLA2GHB, UNG2, HMGCS2, SLC1A1, CEACAM6, TSPAN-1, REPS2, HPX, PDE4DIP, TOM1L1, SCGB2A2, ANXA9, BCAS1, TIMP4, CYP2B6, C9orf116, MSMB, FGFR3, FGF11, BAG1, FOXO3A, KRT16, MALL, KCNG1, IGLC2, KLK8, KRT6B, SNAI1, TMSNB, NRTN, EPHB3, ENO1, SOD2, IGHG1, KLK5, SOS, RARRES1, TTYH1, CD24, MGC27165, SERPINB5, UCHL1, ROPN1, LOC56901, ITGA6, TUBB, UBE4B, IGHM, COL2A1, IMPA2, DRE1, KLK7, TAZ, USP34, C6orf4, ALAD, ARHGDI1, ARHGDI2, ARHGDI3, ARHGDI4, ARHGDI5, ARHGDI6, ARHGDI7, ARHGDI8, ARHGDI9, ARHGDI10, ARHGDI11, ARHGDI12, ARHGDI13, ARHGDI14, ARHGDI15, ARHGDI16, ARHGDI17, ARHGDI18, ARHGDI19, ARHGDI20, ARHGDI21, ARHGDI22, ARHGDI23, ARHGDI24, ARHGDI25, ARHGDI26, ARHGDI27, ARHGDI28, ARHGDI29, ARHGDI30, ARHGDI31, ARHGDI32, ARHGDI33, ARHGDI34, ARHGDI35, ARHGDI36, ARHGDI37, ARHGDI38, ARHGDI39, ARHGDI40, ARHGDI41, ARHGDI42, ARHGDI43, ARHGDI44, ARHGDI45, ARHGDI46, ARHGDI47, ARHGDI48, ARHGDI49, ARHGDI50, ARHGDI51, ARHGDI52, ARHGDI53, ARHGDI54, ARHGDI55, ARHGDI56, ARHGDI57, ARHGDI58, ARHGDI59, ARHGDI60, ARHGDI61, ARHGDI62, ARHGDI63, ARHGDI64, ARHGDI65, ARHGDI66, ARHGDI67, ARHGDI68, ARHGDI69, ARHGDI70, ARHGDI71, ARHGDI72, ARHGDI73, ARHGDI74, ARHGDI75, ARHGDI76, ARHGDI77, ARHGDI78, ARHGDI79, ARHGDI80, ARHGDI81, ARHGDI82, ARHGDI83, ARHGDI84, ARHGDI85, ARHGDI86, ARHGDI87, ARHGDI88, ARHGDI89, ARHGDI90, ARHGDI91, ARHGDI92, ARHGDI93, ARHGDI94, ARHGDI95, ARHGDI96, ARHGDI97, ARHGDI98, ARHGDI99, ARHGDI100, ARHGDI101, ARHGDI102, ARHGDI103, ARHGDI104, ARHGDI105, ARHGDI106, ARHGDI107, ARHGDI108, ARHGDI109, ARHGDI110, ARHGDI111, ARHGDI112, ARHGDI113, ARHGDI114, ARHGDI115, ARHGDI116, ARHGDI117, ARHGDI118, ARHGDI119, ARHGDI120, ARHGDI121, ARHGDI122, ARHGDI123, ARHGDI124, ARHGDI125, ARHGDI126, ARHGDI127, ARHGDI128, ARHGDI129, ARHGDI130, ARHGDI131, ARHGDI132, ARHGDI133, ARHGDI134, ARHGDI135, ARHGDI136, ARHGDI137, ARHGDI138, ARHGDI139, ARHGDI140, ARHGDI141, ARHGDI142, ARHGDI143, ARHGDI144, ARHGDI145, ARHGDI146, ARHGDI147, ARHGDI148, ARHGDI149, ARHGDI150, ARHGDI151, ARHGDI152, ARHGDI153, ARHGDI154, ARHGDI155, ARHGDI156, ARHGDI157, ARHGDI158, ARHGDI159, ARHGDI160, ARHGDI161, ARHGDI162, ARHGDI163, ARHGDI164, ARHGDI165, ARHGDI166, ARHGDI167, ARHGDI168, ARHGDI169, ARHGDI170, ARHGDI171, ARHGDI172, ARHGDI173, ARHGDI174, ARHGDI175, ARHGDI176, ARHGDI177, ARHGDI178, ARHGDI179, ARHGDI180, ARHGDI181, ARHGDI182, ARHGDI183, ARHGDI184, ARHGDI185, ARHGDI186, ARHGDI187, ARHGDI188, ARHGDI189, ARHGDI190, ARHGDI191, ARHGDI192, ARHGDI193, ARHGDI194, ARHGDI195, ARHGDI196, ARHGDI197, ARHGDI198, ARHGDI199, ARHGDI200, ARHGDI201, ARHGDI202, ARHGDI203, ARHGDI204, ARHGDI205, ARHGDI206, ARHGDI207, ARHGDI208, ARHGDI209, ARHGDI210, ARHGDI211, ARHGDI212, ARHGDI213, ARHGDI214, ARHGDI215, ARHGDI216, ARHGDI217, ARHGDI218, ARHGDI219, ARHGDI220, ARHGDI221, ARHGDI222, ARHGDI223, ARHGDI224, ARHGDI225, ARHGDI226, ARHGDI227, ARHGDI228, ARHGDI229, ARHGDI230, ARHGDI231, ARHGDI232, ARHGDI233, ARHGDI234, ARHGDI235, ARHGDI236, ARHGDI237, ARHGDI238, ARHGDI239, ARHGDI240, ARHGDI241, ARHGDI242, ARHGDI243, ARHGDI244, ARHGDI245, ARHGDI246, ARHGDI247, ARHGDI248, ARHGDI249, ARHGDI250, ARHGDI251, ARHGDI252, ARHGDI253, ARHGDI254, ARHGDI255, ARHGDI256, ARHGDI257, ARHGDI258, ARHGDI259, ARHGDI260, ARHGDI261, ARHGDI262, ARHGDI263, ARHGDI264, ARHGDI265, ARHGDI266, ARHGDI267, ARHGDI268, ARHGDI269, ARHGDI270, ARHGDI271, ARHGDI272, ARHGDI273, ARHGDI274, ARHGDI275, ARHGDI276, ARHGDI277, ARHGDI278, ARHGDI279, ARHGDI280, ARHGDI281, ARHGDI282, ARHGDI283, ARHGDI284, ARHGDI285, ARHGDI286, ARHGDI287, ARHGDI288, ARHGDI289, ARHGDI290, ARHGDI291, ARHGDI292, ARHGDI293, ARHGDI294, ARHGDI295, ARHGDI296, ARHGDI297, ARHGDI298, ARHGDI299, ARHGDI300, ARHGDI301, ARHGDI302, ARHGDI303, ARHGDI304, ARHGDI305, ARHGDI306, ARHGDI307, ARHGDI308, ARHGDI309, ARHGDI310, ARHGDI311, ARHGDI312, ARHGDI313, ARHGDI314, ARHGDI315, ARHGDI316, ARHGDI317, ARHGDI318, ARHGDI319, ARHGDI320, ARHGDI321, ARHGDI322, ARHGDI323, ARHGDI324, ARHGDI325, ARHGDI326, ARHGDI327, ARHGDI328, ARHGDI329, ARHGDI330, ARHGDI331, ARHGDI332, ARHGDI333, ARHGDI334, ARHGDI335, ARHGDI336, ARHGDI337, ARHGDI338, ARHGDI339, ARHGDI340, ARHGDI341, ARHGDI342, ARHGDI343, ARHGDI344, ARHGDI345, ARHGDI346, ARHGDI347, ARHGDI348, ARHGDI349, ARHGDI350, ARHGDI351, ARHGDI352, ARHGDI353, ARHGDI354, ARHGDI355, ARHGDI356, ARHGDI357, ARHGDI358, ARHGDI359, ARHGDI360, ARHGDI361, ARHGDI362, ARHGDI363, ARHGDI364, ARHGDI365, ARHGDI366, ARHGDI367, ARHGDI368, ARHGDI369, ARHGDI370, ARHGDI371, ARHGDI372, ARHGDI373, ARHGDI374, ARHGDI375, ARHGDI376, ARHGDI377, ARHGDI378, ARHGDI379, ARHGDI380, ARHGDI381, ARHGDI382, ARHGDI383, ARHGDI384, ARHGDI385, ARHGDI386, ARHGDI387, ARHGDI388, ARHGDI389, ARHGDI390, ARHGDI391, ARHGDI392, ARHGDI393, ARHGDI394, ARHGDI395, ARHGDI396, ARHGDI397, ARHGDI398, ARHGDI399, ARHGDI400	[12]
BRCA1, BRCA2	

DIP2B, MCM6, PLEK2 , FOXI1 , SYT13 , PRDM6 , LONP2, ZNF185, ENTPD4, PPP2R2C, LANCL2, SFTPD, TSGA10, B3GALT2, SEZ6L, KCND2, VSTM2, FANCL, FDPS , VRK2	[13]
HIF1A, VEGF, DUSP1, CXCR4	[14]
IL1B, COL1A1, COL1A2, CTGF, IL10, IL8, SPP1, VCAM1, PGE2, EDN1, BMP6, IL6, PDGFRA, PTHLH, TGFB, LAMC2, IGFBP3, PLAU, TNF, TNFSF11, TNFRSF11A, TNFRSF11B, CXCR4, CXCL12	[15]
CXCR4, CXCL12, HER2	[16]
PASAT1, PHGDH, PSPH, LTBP1, ATF3, CCNA1, MMP13	[17]
ADAM9, ADAMTS1, AREG, EGF, EGFR, ERBB2, HBEGF, MMP1, PTHLH, TNFRSF11A, TNFRSF11B	[18]
CTNNA1, DKK1, PLAUR, SERPINE1, WNT3A	[19]
BMP4, FGF1, FGF17, FGF4, FGF6, FGF8, IGF1, IL11, IL1B, IL6, IL8	[20]
CTTN, CXCL12, CXCR4, IL11, IL6,	[21]
ADAMTS1, EGF, EGFR, MMP1, TNFRSF11A, TNFRSF11B	[22]
HIF1A	[23]
AKT1, AKT3, BMP2, CLEC11A, CXCL12, CXCR4, JAG1, NOV, PDGFA, PGF, PRG2, SPP1, SRC, TGFB1, TGFB3, TNFSF10, VEGFC	[24]
CTGF, NOV, WISP2, WISP3	[25]
CSF1, IL8, PTHLH, TNFRSF11A, TNFRSF11B	[26]
<b>SBCGs compiled for metastasis of primary prostate cancer to bone</b>	
APX1, ANTXR1, CDC23, CDC37, CETN3, CENPE, CCNC, CCNG1, CDK4, CDKN2C, CDKN3, CDKL1, DDB1, E2F1, FEN1, GTPBP4, KAT7, MCM7, MAD2L1, MSH6, NBN, PCNA, EIF2AK2, RAN, RPA2, RPA3, RRM2, SSBP1, SKP1, ADD1, DST, CDH1, CTNNA1, CYB5R3, DSC1, DSG2, ADAM9, FER, TNC, ITGB1, MFGE8, MCAM, ACVRL1, BGN, BST1, IBSP, CDH11, COL1A2, COL6A1, COL6A2, COL7A1, COL11A1, COL16A1, CSF1, DCN, FSTL1, INHA, MGP, SHH, VCAN, COL17A1, ITGB4, PLEC, DSC2, DSP, PKP1, PKP2, PKP3, PKP4, ASRGL1, BMP2, VDR, RUNX2, BGLAP, SPARC, SPP1, TNFRSF11B, TNFSF11, DRG1, PTHRP, EDN1, TNFRSF11A, TP53, HPN, TFF3, BGLAP, ERBB3, PSMD9, CDKN1A, MYCN, AR, HIF1A, MAGEA1, VEGF, KLK3, GDF15, BMP6, ERBB2, LTBP1, MMP9, MMP1, MMP3, PLAUR, HRAS, NRAS, KRT1, PTRF, MDM2, RB1	[27]
HPN	[28]
TFF3	[29]
BGLAP	[30]
ERBB3	[31]
PSMD9, CDKN1A	[27]
ERBB2, EGFR	[32]
PALB, TGFB1, EGFR, BMP	[33]
BIN1, MYC, ABL1	[34]
MAGEA1	[35]

MMP1, MMP2, MMP13, DRG1, PTEN, NME1, CD82, KISS1, BRMS1, MAP2K4, TP53	[36]
IGFBP3, PTH1R, TNFSF11, MMP, MDM2, RB1, TNFRSF11A	[37]
RB1	[38]
CDH11	[39]
LYN, SRC	[40]
ADAMTS1, AREG, EGF, EGFR, HBEGF, PTHLH, TGFA, TNF, TNFRSF11A, TNFRSF11B, VEGFA	[18]
VEGFA, NR1I2	[41]
AKT1, PTHLH, TNFRSF11A, TNFRSF11B	[42]
BMP4, CSF1, DKK1, IL8, NOG, PTHLH, SFRP1, SFRP2, TGFB1, TNFRSF11A, TNFRSF11B	[43]
RAP1GAP, TERF2IP, VTNR	[44]
CXCL12, CXCR4, MAPK1, MAPK3,	[45]
FGF1, FGF17, FGF4, FGF6, FGF8, FGFR3,	[46]

## References

1. Klein A, Olendrowitz C, Schmutzler R, Hampf J, Schlag PM, et al. (2009) Identification of brain- and bone-specific breast cancer metastasis genes. *Cancer letters* 276: 212–220. doi:10.1016/j.canlet.2008.11.017.
2. Li Z, Schem C, Shi YH, Medina D, Zhang M (2008) Increased COX2 expression enhances tumor-induced osteoclastic lesions in breast cancer bone metastasis. *Clinical & experimental metastasis* 25: 389–400. doi:10.1007/s10585-007-9117-3.
3. Taback B, Giuliano AE, Lai R, Hansen N, Singer FR, et al. (2006) Epigenetic analysis of body fluids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients. *Annals of the New York Academy of Sciences* 1075: 211–221. doi:10.1196/annals.1368.029.
4. Bellahcène A, Bachelier R, Detry C, Lidereau R, Clézardin P, et al. (2007) Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. *Breast cancer research and treatment* 101: 135–148. doi:10.1007/s10549-006-9279-8.
5. Maass N, Hojo T, Rösel F, Ikeda T, Jonat W, et al. (2001) Down regulation of the tumor suppressor gene maspin in breast carcinoma is associated with a higher risk of distant metastasis. *Clinical biochemistry* 34: 303–307.
6. Raguz S, De Bella MT, Slade MJ, Higgins CF, Coombes RC, et al. (2005) Expression of RPIP9 (Rap2 interacting protein 9) is activated in breast carcinoma and correlates with a poor prognosis. *International journal of cancer* 117: 934–941. doi:10.1002/ijc.21252.
7. Storga D, Pećina-Slaus N, Pavelić J, Pavelić ZP, Pavelić K (1992) C-Fms is present in primary tumours as well as in their metastases in bone marrow. *International journal of experimental pathology* 73: 527–533.

8. Sloan EK, Stanley KL, Anderson RL (2004) Caveolin-1 inhibits breast cancer growth and metastasis. *Oncogene* 23: 7893–7897. doi:10.1038/sj.onc.1208062.
9. Kwok S, Rittling SR, Partridge NC, Benson CS, Thiyagaraj M, et al. (2009) Transforming growth factor-beta1 regulation of ATF-3 and identification of ATF-3 target genes in breast cancer cells. *Journal of cellular biochemistry* 108: 408–414. doi:10.1002/jcb.22267.
10. Bierie B, Stover DG, Abel TW, Chytil A, Gorska AE, et al. (2008) Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. *Cancer research* 68: 1809–1819. doi:10.1158/0008-5472.CAN-07-5597.
11. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, et al. (2005) Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. *The Journal of Clinical Investigation* 115: 44–55. doi:10.1172/JCI200522320.44.
12. Smid M, Wang Y, Klijn JGM, Siewerts AM, Zhang Y, et al. (2006) Genes associated with breast cancer metastatic to bone. *Journal of clinical oncology* 24: 2261–2267. doi:10.1200/JCO.2005.03.8802.
13. Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, et al. (2007) Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. *Molecular oncology* 1: 160–171. doi:10.1016/j.molonc.2007.03.004.
14. Lu X, Yan CH, Yuan M, Wei Y, Hu G, et al. (2010) In vivo dynamics and distinct functions of hypoxia in primary tumor growth and organotropic metastasis of breast cancer. *Cancer research* 70: 3905–3914. doi:10.1158/0008-5472.CAN-09-3739.
15. Yin JJ, Pollock CB, Kelly K (2005) Mechanisms of cancer metastasis to the bone. *Cell research* 15: 57–62. doi:10.1038/sj.cr.7290266.
16. Sacanna E, Ibrahim T, Gaudio M, Mercatali L, Scarpi E, et al. (2011) The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study. *Oncology* 80: 225–231.
17. Pollari S, Käkönen S-M, Edgren H, Wolf M, Kohonen P, et al. (2011) Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. *Breast cancer research and treatment* 125: 421–430. doi:10.1007/s10549-010-0848-5.
18. Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, et al. (2009) ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. *Genes & Development* 23: 1882–1894. doi:10.1101/gad.1824809.
19. Bu G, Lu W, Liu C-C, Selander K, Yoneda T, et al. (2008) Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. *International Journal of Cancer* 123: 1034–1042. doi:10.1002/ijc.23625.

20. Kozlow W, Guise TA (2005) Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. *Journal of Mammary Gland Biology and Neoplasia* 10: 169–180. doi:10.1007/s10911-005-5399-8.
21. Weigelt B, Peterse J (2005) Breast cancer metastasis: markers and models. *Nature reviews cancer* 5: 591–602. doi:10.1038/nrc1670.
22. Guise TA (2009) Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. *Genes & Development* 23: 2117–2123. doi:10.1101/gad.1854909.
23. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T (2007) Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. *Cancer Research* 67: 4157–4163. doi:10.1158/0008-5472.CAN-06-2355.
24. Zhang XH-F, Wang Q, Gerald W, Hudis C a, Norton L, et al. (2009) Latent bone metastasis in breast cancer tied to Src-dependent survival signals. *Cancer Cell* 16: 67–78. doi:10.1016/j.ccr.2009.05.017.
25. Shimo T, Kubota S, Yoshioka N, Ibaragi S, Isowa S, et al. (2006) Pathogenic Role of Connective Tissue Growth Factor (CTGF/CCN2) in Osteolytic Metastasis of Breast Cancer. *Journal of Bone and Mineral Research* 21: 1045–1059. doi:10.1359/JBMR.060416.
26. Cicek M, Oursler MJ (2006) Breast cancer bone metastasis and current small therapeutics. *Cancer Metastasis Reviews* 25: 635–644. doi:10.1007/s10555-006-9035-x.
27. Knerr K, Ackermann K, Neidhart T, Pyerin W (2004) Bone metastasis: Osteoblasts affect growth and adhesion regulons in prostate tumor cells and provoke osteomimicry. *International journal of cancer* 111: 152–159. doi:10.1002/ijc.20223.
28. Vasioukhin V (2004) Hepsin Paradox Reveals Unexpected Complexity of Metastatic Process. *Cell Cycle* 3: 1394–1397.
29. Faith D a, Isaacs WB, Morgan JD, Fedor HL, Hicks JL, et al. (2004) Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. *The Prostate* 61: 215–227. doi:10.1002/pros.20095.
30. Chung LWK, Hsieh CL, Law A, Sung SY, Gardner TA, et al. (2003) New targets for therapy in prostate cancer: modulation of stromal-epithelial interactions. *Urology* 62: 44–54.
31. Vakar-Lopez F, Cheng C-J, Kim J, Shi GG, Troncoso P, et al. (2004) Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. *The Journal of pathology* 203: 688–695.
32. Morote J, de Torres I, Caceres C, Vallejo C, Schwartz S, et al. (1999) Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatic prostate cancer. *International Journal of Cancer* 84: 421–425.

33. Thomas R, True LD, Lange PH, Vessella RL (2001) Placental bone morphogenetic protein (PLAB) gene expression in normal, pre-malignant and malignant human prostate: relation to tumor development and progression. *International Journal of Cancer* 93: 47–52.
34. Tamada H, Kitazawa R, Gohji K, Kitazawa S (2001) Epigenetic regulation of human bone morphogenetic protein 6 gene expression in prostate cancer. *Journal of bone and mineral research* 16: 487–496. doi:10.1359/jbmr.2001.16.3.487.
35. Kufer P, Zippelius A, Lutterbüse R, Mecklenburg I, Enzmann T, et al. (2002) Heterogeneous Expression of MAGE-A Genes in Occult Disseminated Tumor Cells : A Novel Multimarker Reverse Transcription-Polymerase Chain Reaction for Diagnosis of Micrometastatic Disease. *Cancer research* 62: 251–261.
36. Bandyopadhyay S, Pai SK, Gross SC, Hirota S, Hosobe S, et al. (2003) The Drg-1 Gene Suppresses Tumor Metastasis in Prostate Cancer. *Cancer research* 63: 1731–1736.
37. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, et al. (2003) Prostate Cancer Cells-Osteoblast Interaction Shifts Expression of Growth / Survival-related Genes in Prostate Cancer and Reduces Expression of Osteoprotegerin in Osteoblasts. *Clinical cancer research* 9: 2587–2597.
38. Bookstein R, Rio P, Madreperla S a, Hong F, Allred C, et al. (1990) Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. *Proceedings of the National Academy of Sciences of the United States of America* 87: 7762–7766.
39. Chu K, Cheng C-J, Ye X, Lee Y-C, Zurita AJ, et al. (2008) Cadherin-11 promotes the metastasis of prostate cancer cells to bone. *Molecular Cancer Research* 6: 1259–1267. doi:10.1158/1541-7786.MCR-08-0077.
40. Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, et al. (2009) Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. *British Journal of Cancer* 101: 263–268. doi:10.1038/sj.bjc.6605178.
41. Zhang X, Wang W, True LD, Vessella RL, Takayama TK (2009) Protease-activated receptor-1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis. *The Prostate* 69: 727–736. doi:10.1002/pros.20920.
42. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, et al. (2006) Regulation of cancer cell migration and bone metastasis by RANKL. *Nature* 440: 692–696. doi:10.1038/nature04524.
43. Secondini C, Wetterwald A, Schwaninger R, Thalmann GN, Cecchini MG (2011) The role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasis. *PloS One* 6: e16078. doi:10.1371/journal.pone.0016078.
44. Bailey CL, Kelly P, Casey PJ (2009) Activation of Rap1 promotes prostate cancer metastasis. *Cancer Research* 69: 4962–4968. doi:10.1158/0008-5472.CAN-08-4269.

45. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, et al. (2002) Use of the Stromal Cell-derived Factor-1 / CXCR4 Pathway in Prostate Cancer Metastasis to Bone. *Cancer Research* 62: 1832–1837.
46. Valta MP, Tuomela J, Bjartell A, Valve E, Väänänen HK, et al. (2008) FGF-8 is involved in bone metastasis of prostate cancer. *International Journal of Cancer* 123: 22–31. doi:10.1002/ijc.23422.